Assembly Biosciences (NASDAQ:ASMB) Rating Increased to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Assembly Biosciences (NASDAQ:ASMB) from a buy rating to a strong-buy rating in a report released on Sunday.

A number of other analysts have also recently issued reports on ASMB. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Assembly Biosciences in a report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Wednesday, January 21st. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Assembly Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $41.75.

Assembly Biosciences Price Performance

Shares of ASMB stock opened at $27.70 on Friday. The company’s fifty day simple moving average is $27.93 and its two-hundred day simple moving average is $29.84. Assembly Biosciences has a 1 year low of $7.75 and a 1 year high of $39.71. The stock has a market capitalization of $439.32 million, a price-to-earnings ratio of -37.43 and a beta of 1.11.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings results on Thursday, March 19th. The biopharmaceutical company reported $2.48 EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $2.99. The firm had revenue of $42.47 million during the quarter, compared to analyst estimates of $7.42 million. Assembly Biosciences had a negative return on equity of 5.63% and a negative net margin of 8.47%. Equities research analysts anticipate that Assembly Biosciences will post -6.87 EPS for the current year.

Institutional Investors Weigh In On Assembly Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Ellsworth Advisors LLC bought a new position in Assembly Biosciences in the 3rd quarter worth about $852,000. Commodore Capital LP bought a new stake in shares of Assembly Biosciences during the 3rd quarter valued at about $25,600,000. Farallon Capital Management LLC purchased a new position in shares of Assembly Biosciences during the third quarter worth about $31,426,000. Patient Square Capital LP purchased a new position in shares of Assembly Biosciences during the third quarter worth about $3,461,000. Finally, Palumbo Wealth Management LLC increased its position in shares of Assembly Biosciences by 86.4% in the third quarter. Palumbo Wealth Management LLC now owns 34,798 shares of the biopharmaceutical company’s stock worth $891,000 after purchasing an additional 16,131 shares during the last quarter. Hedge funds and other institutional investors own 19.92% of the company’s stock.

Key Headlines Impacting Assembly Biosciences

Here are the key news stories impacting Assembly Biosciences this week:

• Positive Sentiment: Wall Street Zen upgraded ASMB to a “Strong‑Buy,” which supports bullish investor sentiment and could attract buying interest. Article Title
• Positive Sentiment: HC Wainwright reiterated a Buy rating with a $50 target and raised several multi‑year forecasts (notably FY2026 and FY2028), signaling conviction in ASMB’s longer‑term outlook despite near‑term variability. Article Title
• Neutral Sentiment: Recent compilation of research analyst Q1 earnings predictions provides a range of expectations investors can use to position ahead of the quarterly report; this keeps Q1 results a near‑term catalyst. Article Title
• Negative Sentiment: HC Wainwright trimmed near‑term EPS estimates (Q1–Q3 2026) and cut FY2027 and FY2029 forecasts, which may be pressuring the stock as it raises questions about short‑term profitability and execution risk. MarketBeat ASMB coverage

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.